Clinical trials: Neuroprotective Drugs
Butylphthalide, Cardiac Arrest
Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die.
- Conditions
- Butylphthalide, Cardiac Arrest, Neuroprotective Drugs
- Trial name
- NCT06572085
- Testing
- Butylphthalide and Sodium Chloride Injection, Saline Solution
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Tang Ziren
Premature Birth, Brain Injury
Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study
Preterm babies are at risk of brain injury. Melatonin, a naturally occurring hormone, may reduce this risk. The unborn baby receives melatonin from the mother but following premature delivery there maybe a period of prolonged…
- Trial name
- MIND (NCT00649961)
- Testing
- Melatonin injection
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Imperial College London
Multiple Sclerosis
Protective Role of Oxcarbazepine in Multiple Sclerosis
People with multiple sclerosis (MS) have nerve loss even without acute inflammatory relapses, as obvious in the progressive phase of disease.
- Trial name
- PROXIMUS (NCT02104661)
- Testing
- Oxcarbazepine
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Queen Mary University of London
Parkinson's Disease
Parkinson's Disease Isradipine Safety Study
The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD.
- Trial name
- NCT00753636
- Testing
- Dynacirc CR (Isradipine)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Healthy
Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
The purpose of this research is to determine if patients who receive phenytoin (also commonly known as Dilantin) before taking corticosteroids will show less memory impairment and hypomanic symptoms (feelings of agitation…
- Trial name
- NCT00591006
- Testing
- Phenytoin (brand name Dilantin), Hydrocortisone
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Amyotrophic Lateral Sclerosis
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis
The preclinical rationale for tauroursodeoxycholic acid (TUDCA) use in treating patients with amyotrophic lateral sclerosis (ALS) stems from the demonstration of antioxidant, antiapoptotic and neuroprotective properties of TUDCA…
- Trial name
- TUDCA-ALS (NCT00877604)
- Testing
- tauroursodeoxycholic acid (TUDCA)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Butylphthalide, Cardiac Arrest
Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)
Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain.
- Conditions
- Butylphthalide, Cardiac Arrest, Neuroprotective Drugs
- Trial name
- NCT06353334
- Testing
- Butylphthalide and Sodium Chloride Injection, Saline Solution
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tang Ziren
Parkinson Disease
Effect of Osteopathic Manipulative Medicine on Parkinson Disease
Parkinson's disease (PD) is defined as a progressive disorder of the nervous system that affects the patient's mobility, balance and cognition.
- Trial name
- NCT02107638
- Testing
- OMM treatment arm, Counseling
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- New York Institute of Technology
Small Cell Lung Cancer
A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
Small cell lung cancer is an aggressive neuroendocrine tumour that often presents with extensive (metastatic) disease. Chemotherapy is the mainstay of treatment, with radiotherapy to the primary tumour.
- Trial name
- TULIP (NCT01486459)
- Testing
- Lithium
- Where
- 2 sites in Australia
- Volunteers
- 7 people
- Sponsor
- Barwon Health
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Intracerebral Hemorrhage
Neuroprotectant for Hypertensive Intracerebral Hemorrhage
Cattle encephalon glycoside and ignotin Cattle encephalon glycoside and ignotin (CEGI) injection (drug approval H22025046; Jilin Sihuan Pharmaceutical Co.
- Trial name
- NCT03546283
- Testing
- Cattle Encephalon Glycoside and Ignotin
- Where
- China
- Volunteers
- 422 people
- Sponsor
- Rong Hu, MD
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis, ALS
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive…
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03537807
- Testing
- Riluzole
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Secondary Progressive Multiple Sclerosis
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects approximately 100,000 people in the UK.
- Trial name
- MS-SMART (NCT01910259)
- Testing
- Amiloride, Riluzole, Fluoxetine
- Where
- 13 sites in United Kingdom
- Volunteers
- 445 people
- Sponsor
- University College, London
Nerve Compression Syndromes
Erythropoietin Spinal Cord Compression Randomized Trial
To determine whether erythropoietin, steroids and radiotherapy is safe and feasible to administer to patients with malignant spinal cord compression.
- Trial name
- NCT00220675
- Testing
- Erythropoietin infusion
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Sunnybrook Health Sciences Centre
Acute Stroke
Cytoflavin in Combination With Reperfusion in Stroke Patients
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment…
- Trial name
- NCT05297851
- Testing
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Diabetic Retinopathy
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy
To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes
- Trial name
- EUROCONDOR (NCT01726075)
- Testing
- COLIRIOBCN070660, Brimonidine
- Where
- 11 sites in Denmark, France and 5 more
- Volunteers
- 450 people
- Sponsor
- BCN Peptides
Acute Ischemic Stroke
Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke
The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial. Patients with acute ischemic stroke due to large vessel occlusion undergoing endovascular thrombectomy will be included.
- Trial name
- NCT05367362
- Testing
- Minocyclin
- Sponsor
- State University of New York at Buffalo
Parkinson's Disease
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
GM608 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GAP-PD (NCT01850381)
- Testing
- GM608
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Multiple Sclerosis, Chronic Progressive
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.
- Trial name
- NCT01188811
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development